TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18525001

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two 510‐mg doses of intravenous ferumoxytol within 5 +/- 3 days)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (among patients not receiving erythropoiesis-stimulating agents)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (among patients receiving erythropoiesis-stimulating agents)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Oral iron (200 mg of elemental oral iron daily for 21 days)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Oral iron (among patients not receiving erythropoiesis-stimulating agents)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Oral iron (among patients receiving erythropoiesis-stimulating agents)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 304

Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 304
Study: 15784705

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Eight-point testing
Number of subjects: 200
Study: 12208563

Group type: EXPERIMENTAL
Intervention: Citalopram (n=26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waiting list (n=26)
Number of subjects: 52
Study: 10734504

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 136
Study: 7727815

Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 3121830

Group type: EXPERIMENTAL
Intervention: High heparin dose (137.3 U/day) during 15-hour lipid infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low heparin dose (24 U/day) infused over 24 hours
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both heparin doses at either infusion rate
Number of subjects: 22
Study: 30717757

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) (4 min at 85-95% of peak HRR, 3 days a week for 12 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT) (60-75% of heart rate reserve, 3 days a week for 12 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 21
Study: 27696933

Group type: EXPERIMENTAL
Intervention: High-flavanol and high-theobromine (HFHT) chocolate (30 grams daily for 12 weeks)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Low-flavanol and low-theobromine (LFLT) chocolate (30 grams daily for 12 weeks)
Number of subjects: 131
Study: 24621304

Group type: EXPERIMENTAL
Intervention: Bibliotherapy (self-help manual)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 56
Study: 23557253

Group type: EXPERIMENTAL
Intervention: Child-oriented play group
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Play-as-usual group
Number of subjects: 186

Group type: COMPARATOR
Intervention: Historical community control group
Number of subjects: 186
Study: 21402295

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 104
Study: 17962050

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (500mg capsules twice a day for 3 months)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study: 20380782

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) pharmacotherapy
Number of subjects: 318

Group type: COMPARATOR
Intervention: Monotherapy (IPT or SSRI)
Number of subjects: 318
Study: 16060712

Group type: EXPERIMENTAL
Intervention: tretinoin emollient cream 0.05%
Number of subjects: 204

Group type: COMPARATOR
Intervention: placebo (vehicle emollient cream)
Number of subjects: 204
Study: 11967600

Group type: EXPERIMENTAL
Intervention: Critical incidents (CIs) related to mechanical ventilation
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Non-life-threatening CIs
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Life-threatening CIs
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: CI reporting method
Number of subjects: 137
Study: 9669456

Group type: EXPERIMENTAL
Intervention: Superlux Molar
Number of subjects: 95

Group type: COMPARATOR
Intervention: P‐50 APC
Number of subjects: 95
Study: 7822066

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg taken four times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spironolactone and Control
Number of subjects: 12
Study: 2907849

Group type: EXPERIMENTAL
Intervention: Corticotherapy (group 1, n = 8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Combined cyclophosphamide and steroids (group 2, n = 6)
Number of subjects: 14
Study: 11927734

Group type: EXPERIMENTAL
Intervention: HAART regimen including d4T, 3TC, nevirapine, ritonavir, and nelfinavir
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 3TC
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: nevirapine
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: ritonavir
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: nelfinavir
Number of subjects: 193
Study: 29856651

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise with low repetitions
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate-intensity exercise with moderate repetitions
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-intensity exercise with high repetitions
Number of subjects: 13
Study: 26684607

Group type: EXPERIMENTAL
Intervention: Isavuconazole (372 mg prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1 and 2, then either intravenously or orally once daily)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 527

Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 527
Study: 24906392

Group type: EXPERIMENTAL
Intervention: Problem-solving guided self-help intervention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 124
Study: 22956707

Group type: EXPERIMENTAL
Intervention: Tailored multifaceted intervention program combining professional, organizational, and patient-directed activities, including educational training for general practitioners and support visits by a trained facilitator, tailored to participants' needs and attitudes.
Number of subjects: 712

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 712
Study: 18486287

Group type: EXPERIMENTAL
Intervention: Extended midwifery support (EMS)
Number of subjects: 849

Group type: COMPARATOR
Intervention: Standard postnatal midwifery support (SMS)
Number of subjects: 849
Study: 18520677

Group type: EXPERIMENTAL
Intervention: Provider-initiated HIV counseling and testing
Number of subjects: 754

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 754
Study: 16276136

Group type: EXPERIMENTAL
Intervention: Argatroban (mean dose of 1.8+/−1.1 mg/kg/min for 5.5+/−3.9 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Historical control (no direct thrombin inhibitors)
Number of subjects: 23
Study: 12362931

Group type: EXPERIMENTAL
Intervention: Erythromycin (800 mg per day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clarithromycin (400 mg per day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 9
Study: 10022702

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 1557
Study: 7790637

Group type: EXPERIMENTAL
Intervention: High PerAb students
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low PerAb students
Number of subjects: 51
Study: 2357868

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 57

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 57
Study: 77763

Group type: EXPERIMENTAL
Intervention: Ethanol (3 oz.)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31346969

Group type: EXPERIMENTAL
Intervention: Vitamin D 300,000 IU; n=46
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment with vitamin D 300,000 IU; n=46
Number of subjects: 100
Study: 28515110

Group type: EXPERIMENTAL
Intervention: Biennial FIT screening for women
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Biennial FIT screening for men
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Annual FIT screening for women
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Annual FIT screening for men
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Optimal gender-based screening
Number of subjects: 480

Group type: COMPARATOR
Intervention: Optimal uniform screening
Number of subjects: 480
Study: 26362690

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group-based walking
Number of subjects: 90
Study: 23941026

Group type: EXPERIMENTAL
Intervention: Planas Direct Tracks (PDT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 21749928

Group type: EXPERIMENTAL
Intervention: Resurfacing total hip arthroplasty (R-THA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard total hip arthroplasty (S-THA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both R-THA and S-THA
Number of subjects: 43
Study: 20144167

Group type: EXPERIMENTAL
Intervention: Closure of the peritoneum
Number of subjects: 533

Group type: COMPARATOR
Intervention: Non-closure of the peritoneum
Number of subjects: 533
Study: 17076758

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 12747344

Group type: EXPERIMENTAL
Intervention: Oral pentazocine (100 mg) plus lorazepam (1 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral morphine (30 mg) plus lorazepam (1 mg)
Number of subjects: 100
Study: 11933363

Group type: EXPERIMENTAL
Intervention: Adaptic dressing
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Mepitel dressing
Number of subjects: 99

Group type: COMPARATOR
Intervention: Jelonet dressing
Number of subjects: 99
Study: 8983584

Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasound
Number of subjects: 73
Study: 1619098

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with therapeutic empathy
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with homework compliance
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Patients of novice therapists
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Patients who terminated therapy prematurely
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Patients with borderline personality disorder
Number of subjects: 185
Study: 6532143

Group type: EXPERIMENTAL
Intervention: Alcohol preload
Number of subjects: 0

Group type: COMPARATOR
Intervention: No alcohol preload
Number of subjects: 0
Study: 30457088

Group type: EXPERIMENTAL
Intervention: Fever camp (FC) plus durable wall lining (DWL) with deltamethrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No kala‐azar transmission activity (IRS with deltamethrin, larvicide with temephos, house-to-house search)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fever camp (FC) plus insecticide (deltamethrin) impregnated bed-nets (ITN)
Number of subjects: 0
Study: 29401473

Group type: EXPERIMENTAL
Intervention: Expressive writing of positive emotions for 20 minutes daily for 30 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group writing daily events for 30 days
Number of subjects: 75
Study: 26202039

Group type: EXPERIMENTAL
Intervention: Worker and Workplace Package (WWP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 24631166

Group type: EXPERIMENTAL
Intervention: Quarter zona‐pellucida (ZP) opening by laser‐assisted hatching (QLAH)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 203
Study: 22305836

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/d)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Pravastatin (20 mg/d)
Number of subjects: 164
Study: 21198222

Group type: EXPERIMENTAL
Intervention: Reading condition (participants asked to spend 20 minutes re-reading the feedback)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Recall condition (participants asked to spend 20 minutes writing down as much of the information from the feedback as they could remember)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Typical condition (participants simply sent home)
Number of subjects: 98
Study: 17438220

Group type: EXPERIMENTAL
Intervention: Natalizumab (monotherapy in AFFIRM and add-on to interferon beta-1a in SENTINEL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (non-natalizumab)
Number of subjects: 0
Study: 16085513

Group type: EXPERIMENTAL
Intervention: Nicotine replacement, antidepressants, and psychological interventions
Number of subjects: 428

Group type: COMPARATOR
Intervention: No history of childhood ADHD
Number of subjects: 428
Study: 11811936

Group type: EXPERIMENTAL
Intervention: IL‐2 liposomes (12 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo liposomes (12 weeks)
Number of subjects: 15
Study: 9880175

Group type: EXPERIMENTAL
Intervention: Postoperative radiation treatment of 3 x 3.3 Gy
Number of subjects: 154

Group type: COMPARATOR
Intervention: NSAID therapy (3 x 50 mg of diclofenac per day for 3 weeks)
Number of subjects: 154
Study: 7973766

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus cisplatin
Number of subjects: 612

Group type: COMPARATOR
Intervention: Vindesine plus cisplatin
Number of subjects: 612

Group type: COMPARATOR
Intervention: Single-agent vinorelbine
Number of subjects: 612
Study: 2739612

Group type: EXPERIMENTAL
Intervention: Smokescreen programme
Number of subjects: 121

Group type: COMPARATOR
Intervention: General practice antismoking advice
Number of subjects: 121
Study: 1070803

Group type: EXPERIMENTAL
Intervention: Frozen carbon dioxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frigen
Number of subjects: 0
Study: 30042140

Group type: EXPERIMENTAL
Intervention: MRI intervention group
Number of subjects: 356

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 356
Study: 27687824

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (RT)
Number of subjects: 124
Study: 25602634

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (nepafenac vehicle)
Number of subjects: 125
Study: 24990779

Group type: EXPERIMENTAL
Intervention: toothpaste Mexidol Dent Fito (20 patients)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: mouthwash Mexidol Dent Professional (23 patients)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: both toothpaste and mouthwash (21 patients)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (19 patients)
Number of subjects: 83
Study: 22388798

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 39114

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 39114

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 39114

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 39114
Study: 19323801

Group type: EXPERIMENTAL
Intervention: 2 mg riboflavin
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 4 mg riboflavin
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 123
Study: 17689196

Group type: EXPERIMENTAL
Intervention: Assessment of simulated bad news consultations
Number of subjects: 70
Study: 15451219

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg once a day
Number of subjects: 946

Group type: COMPARATOR
Intervention: Imatinib 400 mg twice a day
Number of subjects: 946
Study: 11376307

Group type: EXPERIMENTAL
Intervention: 5 mg oral nicorandil 3 times daily (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 30
Study: 9763724

Group type: EXPERIMENTAL
Intervention: Artesunate (700 mg for 5 days)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Quinine + Tetracycline (7-day regimen)
Number of subjects: 137
Study: 7924750

Group type: EXPERIMENTAL
Intervention: IFN-alpha (49 cases)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: IFN-beta (16 cases)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: IFN treatment
Number of subjects: 65
Study: 3047220

Group type: EXPERIMENTAL
Intervention: Sucralfate emulsion (1 g four times daily)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 97
Study: 2035471

Group type: EXPERIMENTAL
Intervention: 50 mg beta-carotene per day
Number of subjects: 582
Study: 766573

Group type: EXPERIMENTAL
Intervention: Computer-based system for detecting ventricular arrhythmias
Number of subjects: 15
Study: 31596415

Group type: EXPERIMENTAL
Intervention: Menthol chewing gum
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 102
Study: 27530529

Group type: EXPERIMENTAL
Intervention: Usual education plus self-care instruction for symptoms and quality of life issues, communication coaching, and symptom tracking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual education about symptoms and quality of life topics
Number of subjects: 0
Study: 26515686

Group type: EXPERIMENTAL
Intervention: T2 quantification by MRI
Number of subjects: 190
Study: 23642641

Group type: EXPERIMENTAL
Intervention: Tactile massage (TM)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Relaxation exercises
Number of subjects: 46
Study: 21663425

Group type: EXPERIMENTAL
Intervention: Aripiprazole (2-15 mg/day)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Prior placebo
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Prior aripiprazole
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 330
Study: 19252247

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF inhibitors
Number of subjects: 0
Study: 18001541

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) treatment in Group A
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) treatment in Group C
Number of subjects: 30
Study: 15112008

Group type: EXPERIMENTAL
Intervention: 2.5% suspension concentrate (SC) deltamethrin applied with manual compression sprayers
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: 2.5% suspension concentrate (SC) deltamethrin applied with power sprayers
Number of subjects: 667

Group type: COMPARATOR
Intervention: 1.5% emulsifiable concentrate (EC) deltamethrin
Number of subjects: 667

Group type: COMPARATOR
Intervention: 10% EC cis-permethrin
Number of subjects: 667
Study: 11215604

Group type: EXPERIMENTAL
Intervention: DE CL group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CL group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 9728566

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 12
Study: 7844976

Group type: EXPERIMENTAL
Intervention: Live workshop training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video training
Number of subjects: 0
Study: 3128100

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU/d for 5 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29794782

Group type: EXPERIMENTAL
Intervention: Intra-coronary administration of tirofiban through aspiration catheter
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intra-coronary administration of tirofiban through guiding catheter
Number of subjects: 89
Study: 27489202

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 3% gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salicylic acid 2% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 0
Study: 25198263

Group type: EXPERIMENTAL
Intervention: Day care management (n=42)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Inpatient management (n=56)
Number of subjects: 98
Study: 22608481

Group type: EXPERIMENTAL
Intervention: Tomographic neurofeedback (tNF) training using theta‐beta frequency and slow cortical potential (SCP) protocols
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Tomographic neurofeedback (tNF) training
Number of subjects: 13
Study: 19834806

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solutions (OSPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 0
Study: 18030500

Group type: EXPERIMENTAL
Intervention: Tangerine juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 10
Study: 16201292

Group type: EXPERIMENTAL
Intervention: Yaoliuan capsule
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 323
Study: 12898897

Group type: EXPERIMENTAL
Intervention: Chronic alcohol consumption (5-37 years)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (18 persons who rarely drank alcohol)
Number of subjects: 79
Study: 10569360

Group type: EXPERIMENTAL
Intervention: Nonabsorbable suture anchors
Number of subjects: 40

Group type: COMPARATOR
Intervention: Absorbable suture anchors
Number of subjects: 40
Study: 8829933

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia (induction: 2-3 mg kg-1, maintenance: 6-10 mg kg-1 h-1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone/halothane anaesthesia (induction: 4-6 mg kg-1, maintenance: halothane 0.8-1.5%)
Number of subjects: 60
Study: 1984348

Group type: EXPERIMENTAL
Intervention: Exercise (5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no exercise, 5 days)
Number of subjects: 20